Skip Navigation
Genetics Home Reference: your guide to understanding genetic conditions
http://ghr.nlm.nih.gov/     A service of the U.S. National Library of Medicine®

ACP5

Reviewed December 2013

What is the official name of the ACP5 gene?

The official name of this gene is “acid phosphatase 5, tartrate resistant.”

ACP5 is the gene's official symbol. The ACP5 gene is also known by other names, listed below.

What is the normal function of the ACP5 gene?

The ACP5 gene provides instructions for making an enzyme called tartrate-resistant acid phosphatase type 5 (TRAP). The TRAP enzyme primarily regulates the activity of a protein called osteopontin, which is produced in bone cells called osteoclasts and in immune cells. Osteopontin performs a variety of functions in these cells. Two versions (isoforms) of the TRAP enzyme are produced: TRAP5a is found primarily in immune cells and TRAP5b is found primarily in bone cells called osteoclasts.

Osteoclasts are specialized cells that break down and remove (resorb) bone tissue that is no longer needed. These cells are involved in bone remodeling, which is a normal process that replaces old bone tissue with new bone. During bone remodeling, osteopontin is turned on (activated), allowing osteoclasts to attach (bind) to bones. When the breakdown of bone is complete, TRAP5b turns off (inactivates) osteopontin, causing the osteoclasts to release themselves from bone.

In the immune system, osteopontin is found primarily in cells called macrophages and dendritic cells. The protein helps fight infection by promoting inflammation, regulating immune cell activity, and turning on various immune system cells that are necessary to fight off foreign invaders such as bacteria and viruses. Like TRAP5b in bone cells, the TRAP5a enzyme inactivates osteopontin in macrophages and dendritic cells when it is no longer needed.

How are changes in the ACP5 gene related to health conditions?

spondyloenchondrodysplasia with immune dysregulation - caused by mutations in the ACP5 gene

At least 10 mutations in the ACP5 gene have been found to cause spondyloenchondrodysplasia with immune dysregulation (SPENCDI). This condition is characterized by abnormalities in bone growth and immune system function. The ACP5 gene mutations that cause SPENCDI typically change single protein building blocks (amino acids) in the TRAP enzyme or result in the production of an abnormally short enzyme. These mutations affect both TRAP isoforms and impair or eliminate TRAP's ability to inactivate osteopontin. As a result, osteopontin is abnormally active, prolonging bone breakdown by osteoclasts and triggering abnormal inflammation and immune responses by immune cells.

In people with SPENCDI, increased bone breakdown contributes to the skeletal abnormalities, including irregularly shaped bones and short stature. An overactive immune system leads to increased susceptibility to autoimmune disorders, which occur when the immune system malfunctions and attacks the body's own tissues and organs. Immune system abnormalities also impair the body's normal response to harmful invaders, resulting in frequent infections. SPENCDI has several additional features, including movement disorders and intellectual disability, but it is unknown how changes in TRAP enzyme function lead to these other signs and symptoms.

Where is the ACP5 gene located?

Cytogenetic Location: 19p13.2

Molecular Location on chromosome 19: base pairs 11,574,659 to 11,578,985

The ACP5 gene is located on the short (p) arm of chromosome 19 at position 13.2.

The ACP5 gene is located on the short (p) arm of chromosome 19 at position 13.2.

More precisely, the ACP5 gene is located from base pair 11,574,659 to base pair 11,578,985 on chromosome 19.

See How do geneticists indicate the location of a gene? (http://ghr.nlm.nih.gov/handbook/howgeneswork/genelocation) in the Handbook.

Where can I find additional information about ACP5?

You and your healthcare professional may find the following resources about ACP5 helpful.

You may also be interested in these resources, which are designed for genetics professionals and researchers.

What other names do people use for the ACP5 gene or gene products?

  • PPA5_HUMAN
  • tartrate-resistant acid ATPase
  • tartrate-resistant acid phosphatase type 5
  • TRAP
  • TrATPase

See How are genetic conditions and genes named? (http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/naming) in the Handbook.

What glossary definitions help with understanding ACP5?

acids ; autoimmune ; bacteria ; bone remodeling ; breakdown ; cell ; dephosphorylation ; disability ; enzyme ; gene ; immune system ; infection ; inflammation ; isoforms ; phosphatase ; protein ; short stature ; stature ; susceptibility ; tissue

You may find definitions for these and many other terms in the Genetics Home Reference Glossary (http://ghr.nlm.nih.gov/glossary).

References

  • Behrens TW, Graham RR. TRAPing a new gene for autoimmunity. Nat Genet. 2011 Feb;43(2):90-1. doi: 10.1038/ng0211-90. (http://www.ncbi.nlm.nih.gov/pubmed/21270835?dopt=Abstract)
  • Briggs TA, Rice GI, Daly S, Urquhart J, Gornall H, Bader-Meunier B, Baskar K, Baskar S, Baudouin V, Beresford MW, Black GC, Dearman RJ, de Zegher F, Foster ES, Francès C, Hayman AR, Hilton E, Job-Deslandre C, Kulkarni ML, Le Merrer M, Linglart A, Lovell SC, Maurer K, Musset L, Navarro V, Picard C, Puel A, Rieux-Laucat F, Roifman CM, Scholl-Bürgi S, Smith N, Szynkiewicz M, Wiedeman A, Wouters C, Zeef LA, Casanova JL, Elkon KB, Janckila A, Lebon P, Crow YJ. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet. 2011 Feb;43(2):127-31. doi: 10.1038/ng.748. Epub 2011 Jan 9. (http://www.ncbi.nlm.nih.gov/pubmed/21217755?dopt=Abstract)
  • Hayman AR. Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity. 2008 Apr;41(3):218-23. doi: 10.1080/08916930701694667. Review. (http://www.ncbi.nlm.nih.gov/pubmed/18365835?dopt=Abstract)
  • Lausch E, Janecke A, Bros M, Trojandt S, Alanay Y, De Laet C, Hübner CA, Meinecke P, Nishimura G, Matsuo M, Hirano Y, Tenoutasse S, Kiss A, Rosa RF, Unger SL, Renella R, Bonafé L, Spranger J, Unger S, Zabel B, Superti-Furga A. Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat Genet. 2011 Feb;43(2):132-7. doi: 10.1038/ng.749. Epub 2011 Jan 9. (http://www.ncbi.nlm.nih.gov/pubmed/21217752?dopt=Abstract)
  • NCBI Gene (http://www.ncbi.nlm.nih.gov/gene/54)
  • OMIM: PHOSPHATASE, ACID, TYPE 5, TARTRATE-RESISTANT (http://omim.org/entry/171640)

 

The resources on this site should not be used as a substitute for professional medical care or advice. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional. See How can I find a genetics professional in my area? (http://ghr.nlm.nih.gov/handbook/consult/findingprofessional) in the Handbook.

 
Reviewed: December 2013
Published: December 16, 2014